Aura Biosciences (AURA) Accounts Payables (2020 - 2026)

Aura Biosciences has reported Accounts Payables for 7 years, with the latest figure at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 28.27% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $2.6 million (up 28.27% YoY), and the FY2025 full-year result was $1.5 million, down 32.77% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.6 million, up from $1.5 million in the prior quarter.
• The five-year high for Accounts Payables was $2.9 million in Q4 2022, with the low at $553000.0 in Q2 2023.
• Historically, Accounts Payables has averaged $1.7 million across 5 years, with a median of $1.8 million in 2023.
• Annual changes were most pronounced in 2023 — Accounts Payables tumbled 53.84% — and 2024, when it jumped 163.83%.
• Aura Biosciences' Accounts Payables stood at $2.9 million in 2022, then plunged by 38.82% to $1.8 million in 2023, then climbed by 28.93% to $2.3 million in 2024, then sank by 32.77% to $1.5 million in 2025, then jumped by 66.11% to $2.6 million in 2026.
• The last three Accounts Payables figures came in at $2.6 million (Q1 2026), $1.5 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.